One likely cause of acquired resistance is the downregulation of CD38 expression in both bone marrow and circulating myeloma cells after a single daratumumab infusion [69,70]; thus, the use of anti-CD38 therapy in multiple myeloma patients has revealed that these antibodies may be most efficacious when delivered as part of a combination treatment strategy. Here, CD38 is linked to AL amyloidosis.